Analysts anticipate a Q2 2026 loss of $1.27 per share on revenue of $182.5 million, with the current stock price of $52.42 significantly trailing the consensus price target of $94.68. Investors are primarily focused on the quarterly net sales performance of Crysvita, the company's flagship treatment for X-linked hypophosphatemia, which remains the core driver of top-line growth.
Beyond immediate commercial metrics, the market is looking for regulatory updates on the gene therapy pipeline, specifically the Phase 3 programs for GSDIa and OTC deficiency. Clinical progress for GTX-102 in Angelman syndrome also remains a critical sentiment driver as the company moves toward potential late-stage filings.